Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel

@article{Montouris2015EfficacyAS,
  title={Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel},
  author={Georgia Montouris and Haichen Yang and Betsy Anne Williams and Sharon Zhou and Antonio Laurenza and Randi Fain},
  journal={Epilepsy Research},
  year={2015},
  volume={114},
  pages={131-140}
}
OBJECTIVE To evaluate the efficacy and safety of perampanel in patients with drug-resistant partial seizures after the conversion from double-blind placebo in three phase III studies to open-label perampanel, and to assess the impact of perampanel titration rates through a comparison of weekly vs biweekly dose increases. METHODS Patients who completed the three multinational, double-blind, placebo-controlled, phase III core studies (studies 304, 305, or 306) were eligible to enroll in the… CONTINUE READING

7 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Perampanel was well tolerated , with the most common treatment - emergent adverse events being dizziness , somnolence , weight increase , irritability , fatigue , and headache .
FatigueNo subtypeHeadache
Perampanel was well tolerated , with the most common treatment - emergent adverse events being dizziness , somnolence , weight increase , irritability , fatigue , and headache .
HeadacheNo subtypeFatigue
Perampanel was well tolerated , with the most common treatment - emergent adverse events being dizziness , somnolence , weight increase , irritability , fatigue , and headache .
Perampanel was well tolerated , with the most common treatment - emergent adverse events being dizziness , somnolence , weight increase , irritability , fatigue , and headache .
Perampanel was well tolerated , with the most common treatment - emergent adverse events being dizziness , somnolence , weight increase , irritability , fatigue , and headache .
All Topics